{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"}],"units":"Participants"}],"description":"Clinical management changes were assessed using surveys of Intended Management to determine the percent change in clinical management after 68Ga-PSMA-11 PET.","groups":[{"description":"Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.","id":"OG000","title":"Ga-68 Labeled PSMA-11 PET"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Percentage of Participants With Change in Clinical Management","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}